JOURNAL
Current Issue
Journal Archive
 

Chief Editor -
Abdulrazak Abyad MD, MPH, MBA, AGSF, AFCHSE

.........................................................

Publisher -
Lesley Pocock
medi+WORLD International
AUSTRALIA
Email
: lesleypocock@mediworld.com.au
publishermwi@gmail.com
.........................................................

Editorial Enquiries -
abyad@cyberia.net.lb
.........................................................

Advertising Enquiries -
lesleypocock@mediworld.com.au
.........................................................

While all efforts have been made to ensure the accuracy of the information in this journal, opinions expressed are those of the authors and do not necessarily reflect the views of The Publishers, Editor or the Editorial Board. The publishers, Editor and Editorial Board cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; or the views and opinions expressed. Publication of any advertisements does not constitute any endorsement by the Publishers and Editors of the product advertised.

The contents of this journal are copyright. Apart from any fair dealing for purposes of private study, research, criticism or review, as permitted under the Australian Copyright Act, no part of this program may be reproduced without the permission of the publisher.

WFM / MEJFM May 2025

Acarbose in the treatment of chronic obstructive pulmonary disease


Mehmet Rami Helvaci (1), Hulya Halici (2), Kevser Erdogan (3), Alper Sevinc (1), Celaletdin Camci (1), Abdulrazak Abyad (4), Lesley Pocock (5)

(1) Specialist of Internal Medicine, MD, Turkey
(2) Manager of Writing and Statistics, Turkey
(3) Specialist of Public Health, MD, Turkey
(4) Consultant, Internal Medicine and Geriatrics, DASH, Kuwait,
Chairman, Middle-East Academy for Medicine of Aging
(5) medi+WORLD International, Australia

Correspondence
Prof Dr Mehmet Rami Helvaci
07400, ALANYA, TurkeyPhone: 00-90-506-4708759
Email: mramihelvaci@hotmail.com

Received: March 2025. Accepted: April 2025; Published:May 1, 2025.Citation: Helvaci MR et al. Acarbose in the treatment of chronic obstructive pulmonary disease. May 2025; 23(2): 37-52
DOI: 10.5742/MEWFM.2025.695257865


Abstract

Background: Atherosclerosis may be the main cause of aging and death.

Methods: All patients with sickle cell diseases (SCD) were included.

Results: We studied 222 males and 212 females with mean ages of 30.8 vs 30.3 years, p>0.05, respectively. Smoking (23.8% vs 6.1%, p<0.001), alcohol (4.9% vs 0.4%, p<0.001), transfused red blood cells (RBC) in their lifespans (48.1 vs 28.5 units, p=0.000), disseminated teeth losses (5.4% vs 1.4%, p<0.001), ileus (7.2% vs 1.4%, p<0.001), chronic obstructive pulmonary disease (COPD) (25.2% vs 7.0%, p<0.001), coronary heart disease (CHD) (18.0% vs 13.2%, p<0.05), cirrhosis (8.1% vs 1.8%, p<0.001), leg ulcers (19.8% vs 7.0%, p<0.001), clubbing (14.8% vs 6.6%, p<0.001), chronic renal disease (CRD) (9.9% vs 6.1%, p<0.05), and stroke (12.1% vs 7.5%, p<0.05) were all higher in males.

Conclusion: As an accelerated atherosclerosis, hardened RBC-induced capillary endothelial damage initiating at birth terminates with multiorgan failures in early years of life in SCD. Excess fat tissue may be much more important than smoking and alcohol for atherosclerosis because excess weight-induced diabetes mellitus is the most common cause of CRD, and CHD and stroke are the main causes of deaths even in the COPD. The efficacy of acarbose to lower blood glucose by preventing breakdown of starch into sugar in the small intestine is obvious. Since acarbose is a safe, cheap, oral, and effective drug for excess weight, it should be advised in COPD because there are nearly 20 kg of excess fat even between upper and lower borders of normal weight in adults.

Key words: Acarbose, chronic obstructive pulmonary disease, sickle cell diseases, excess fat tissue, smoking, vascular endothelial inflammation, atherosclerosis





.................................................................................................................

I About MEJFM I Journal I Advertising I Author Info I Editorial Board I Resources I Contact us I Journal Archive I MEPRCN I Noticeboard I News and Updates
Disclaimer - ISSN 148-4196 - © Copyright 2007 medi+WORLD International Pty. Ltd. - All rights reserved